Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Altimmune presented new 48-week data from its IMPACT Phase 2b trial at EASL 2026, showing pemvidutide significantly reduced triglycerides by 23.7% and total cholesterol by 15.4% in MASH patients. The treatment also drove a 7.5% weight loss, reduced waist circumference by 5.3 cm, and lowered systolic blood pressure by 4.0 mmHg, with a favorable safety profile and only 1% discontinuation due to adverse events.
Key figures
- Drug Name
- pemvidutide
- Phase Of Trial
- Phase 2b
- Weight loss
- 7.5%
- Bmi reduction
- -3.0 kg/m2
- Systolic bp reduction
- -4.0 mmHg
- Diastolic bp reduction
- -2.2 mmHg
- Triglyceride reduction
- -23.7%
- Discontinuation rate ae
- 1%
- Total cholesterol reduction
- -15.4%
- Waist circumference reduction
- -5.3 cm
- Primary endpoint responder rate 1.2mg
- 27.8%
- Primary endpoint responder rate 1.8mg
- 32.4%
- Primary endpoint responder rate placebo
- 3.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.